Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Headache Disorder Clear all
Completed Not applicable Interventional Results available

Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention

NCT04828707
View directory record Official record
Conditions
Migraine
Interventions
Nerivio active device, Nerivio sham device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Phoenix, Arizona • Carlsbad, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Nov 15, 2026, 2:08 PM EST
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)

NCT03229798
View directory record Official record
Conditions
Migraine Disorders
Interventions
Sumatriptan Succinate Oral Tablet, Transdermal delivery of sumatriptan succinate
Drug · Combination Product
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Nov 15, 2026, 2:08 PM EST
Recruiting Phase 4 Interventional

A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache

NCT06473597
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Rizatriptan Benzoate
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

NCT03901482
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebos
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
117
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

NCT03447782
View directory record Official record
Conditions
New Daily Persistent Headache (NDPH)
Interventions
Naltrexone HCl (Bulk) Powder
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Nov 15, 2026, 2:08 PM EST
Recruiting Not applicable Interventional

Mind Body Intervention for Chronic Migraine Headaches

NCT06690060
View directory record Official record
Conditions
Migraines, Chronic Pain
Interventions
Mind-Body Intervention
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Completed No phase listed Observational

Nerivio Long-term Usage in Patients With Migraine

NCT06738056
View directory record Official record
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

NINDS CRC Chronic Migraine Treatment Trial

NCT00772031
View directory record Official record
Conditions
Chronic Migraine
Interventions
propranolol LA, topiramate, placebo
Drug
Lead sponsor
Anne Lindblad
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Tuscon, Arizona • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Nov 15, 2026, 2:08 PM EST
Terminated No phase listed Observational

Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone

NCT03762902
View directory record Official record
Conditions
Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases
Interventions
Not listed
Lead sponsor
Lifegraph Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Detroit, Michigan • West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Nov 15, 2026, 2:08 PM EST
Not yet recruiting Phase 2 Interventional

Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine

NCT07764783
View directory record Official record
Conditions
Migraine, Facial Pain or Pressure, Headache
Interventions
Topical solution of 4% lidocaine, Saline 0.9%
Drug
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Completed Not applicable Interventional Results available

A Study of Home-Delivered Neurostimulation for Migraine

NCT03874351
View directory record Official record
Conditions
Migraine Disorders
Interventions
non-invasive transcranial direct current stimulation (tDCS)
Device
Lead sponsor
MJHS Institute for Innovation in Palliative Care
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 3 Interventional

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

NCT00228605
View directory record Official record
Conditions
Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
38
States / cities
Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 3 Interventional Results available

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

NCT03559257
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Phoenix, Arizona • San Diego, California • Ocoee, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Nov 15, 2026, 2:08 PM EST
Completed Not applicable Interventional

NYU Langone Health Headache Center Learning Migraine Self-Management Techniques Study

NCT06077812
View directory record Official record
Conditions
Migraine
Interventions
RELAXaHEAD Smartphone App, In-Person Training, Virtual Training
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Nov 15, 2026, 2:08 PM EST
Not listed Phase 3 Interventional

SPG Block for Acute Pediatric Migraine

NCT03984045
View directory record Official record
Conditions
Migraine in Children, Sphenopalatine Neuralgia, Migraine in Adolescence
Interventions
Lidocaine topical, Prochlorperazine Injection
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
10 Years to 20 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Nov 15, 2026, 2:08 PM EST
Completed Not applicable Interventional Results available

Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine

NCT01532830
View directory record Official record
Conditions
Migraine
Interventions
n-VNS
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
San Francisco, California • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Topical Intra-Oral Ketoprofen for Migraine Prevention

NCT01211795
View directory record Official record
Conditions
Migraine
Interventions
topical intraoral ketoprofen gel, Placebo Gel
Drug · Other
Lead sponsor
Behar, Caren, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Nov 15, 2026, 2:08 PM EST
Completed Not applicable Interventional

A Nutritional Intervention for Migraines-2

NCT01699009
View directory record Official record
Conditions
Migraines
Interventions
Plant based diet, an unrestricted diet
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Nov 15, 2026, 2:08 PM EST
Not listed No phase listed Observational

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

NCT06154070
View directory record Official record
Conditions
Migraine Disorders
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
Ki Health Partners. LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Nov 15, 2026, 2:08 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions

NCT01161654
View directory record Official record
Conditions
Migraine
Interventions
naratriptan hydrochoride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 15, 2026, 2:08 PM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

Galantamine in the Treatment of Post-Traumatic Headache

NCT00219869
View directory record Official record
Conditions
Post-Traumatic Headache, Head Trauma,Closed, Retention Disorders,Cognitive
Interventions
Galantamine
Drug
Lead sponsor
Rapoport, Alan, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 4 Interventional Results available

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

NCT04252742
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Recruiting Phase 4 Interventional

Tirzepatide in Idiopathic Intracranial Hypertension Trial

NCT07191873
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension (IIH)
Interventions
Tirzepatide, Tirzepatide Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST